REG - Roquefort Theraptcs. - Appointment of Joint Broker

Roquefort TherapeuticsAnnouncement

20/07/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220720:nRST0445Ta&default-theme=true

RNS Number : 0445T  Roquefort Therapeutics PLC  20 July 2022

20 July 2022

 

Roquefort Therapeutics plc

("Roquefort Therapeutics" or the "Company")

 

Appointment of Joint Broker

 

Roquefort Therapeutics (LSE:ROQ,OTCQB:ROQAF), the Main Market listed biotech
company focused on early-stage opportunities in the biotechnology sector, is
pleased to announce the appointment of  Hybridan LLP ("Hybridan") as its
Joint Broker with immediate effect.

 

Stephen West, Roquefort Therapeutics Executive Chairman, commented:

"We are delighted to be working with Hybridan going forward.  Hybridan has a
deep understanding of the life sciences sector particularly within small caps,
and their experience will be invaluable to Roquefort Therapeutics as we target
further institutional investors and family offices."

 

-Ends-

 

 
Enquiries:
 Roquefort Therapeutics plc
 Stephen West (Chairman)                    +44 (0)20 3290 9339

 Hybridan LLP (Joint Broker)

 Claire Louise Noyce                        +44 (0)203 764 2341

 Optiva Securities Limited (Joint Broker)
 Christian Dennis                           +44 (0)20 3411 1881

 Buchanan (Public Relations)

 Ben Romney / Jamie Hooper / George Beale   +44 (0)20 7466 5000

 

For further information on Roquefort Therapeutics, please visit
www.roquefortplc.com (http://www.roquefortplc.com) and @RoquefortTherap on
Twitter.

 

LEI: ‎254900P4SISIWOR9RH34

 

About Roquefort Therapeutics

Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF) is a Main Market listed biotech
company developing products through the pre-clinical phase prior to partnering
or selling to big pharma.  The Company is focused on developing first in
class Midkine inhibiting drugs for the treatment of cancer.

 

Through extensive research resulting in validation through publication in over
1,000 scientific publications, Roquefort Therapeutics has identified the
potential to exploit the broad therapeutic potential of Midkine for a number
of clinical indications of significant unmet needs. Roquefort Therapeutics
holds an exclusive licence to the largest global IP portfolio on Midkine. The
Midkine blocking drug development markets have significant global market
potential (in the multi-billion dollars). Roquefort Therapeutics's
pre-clinical programme is currently underway with an initial focus on cancer.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  APPDZGMNRLFGZZM